Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for STE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for STE and 80,000+ other tickers.
See exactly how STE's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for STE and 80,000+ other tickers.
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
DUBLIN, IRELAND, Oct. 20, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 second quarter results at 9:00 a.m. ET on November 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
Perpetual Ltd grew its holdings in shares of STERIS plc (NYSE: STE) by 9.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,157 shares of the medical equipment provider's stock after purchasing an additional 5,974 shares during the period. Perpetual Ltd owned approximately
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)PR NewswirePITTSBURGH, Oct. 12, 2026PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medica
PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting healthcare professionals, and delivering innovative solutions to the surgical environment.